Cite
Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA
MLA
Qiongyu Hao, et al. “Comp34 Displays Potent Preclinical Antitumor Efficacy in Triple-Negative Breast Cancer via Inhibition of NUDT3-AS4, a Novel Oncogenic Long Noncoding RNA.” Cell Death and Disease, vol. 11, no. 12, Dec. 2020, pp. 1–18. EBSCOhost, https://doi.org/10.1038/s41419-020-03235-w.
APA
Qiongyu Hao, Piwen Wang, Pranabananda Dutta, Seyung Chung, Qun Li, Kun Wang, Jieqing Li, Wei Cao, Wenhong Deng, Qing Geng, Katrina Schrode, Magda Shaheen, Ke Wu, Donghui Zhu, Qiao-Hong Chen, Guanglin Chen, Yahya Elshimali, Jay Vadgama, & Yong Wu. (2020). Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death and Disease, 11(12), 1–18. https://doi.org/10.1038/s41419-020-03235-w
Chicago
Qiongyu Hao, Piwen Wang, Pranabananda Dutta, Seyung Chung, Qun Li, Kun Wang, Jieqing Li, et al. 2020. “Comp34 Displays Potent Preclinical Antitumor Efficacy in Triple-Negative Breast Cancer via Inhibition of NUDT3-AS4, a Novel Oncogenic Long Noncoding RNA.” Cell Death and Disease 11 (12): 1–18. doi:10.1038/s41419-020-03235-w.